Other information
Gender equality index 2019 Gender equality index
Masivet
Mast cell tumours (MCTs) are the most common cutaneous malignancies in dogs. Masivet® is an effective, well-tolerated and proven treatment for dog MCT and was the first tyrosine kinase inhibitor registered in veterinary oncology when it was approved by the European Medicine Agency in 2008. AB Science celebrated in 2018 the 10th anniversary of the…
Message from the CEO
“AB Science was founded in 2001 by a team of scientists in order to develop new drugs targeting indications with unmet medical needs, in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. In human medicine, our masitinib pipeline is well advanced with several phase 3 studies in oncology and non-oncology diseases and…
Masitinib General overview
Masitinib, AB Science main compound, is a selective tyrosine kinase inhibitor which is currently developed in three therapeutic areas: neurology, inflammatory diseases and oncology. As of today, masitinib is mainly developed in the following indications: amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer disease, mastocytosis, severe asthma, prostate cancer and pancreatic cancer. Masitinib pipeline is well advanced with…
Masitinib in Neurology
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative, life-threatening disease characterized by progressive muscular paralysis reflecting degeneration of motor neurons. While the average survival time is 3 years, about 10 percent of people with ALS will survive 10 years. Preclinical studies show that masitinib is capable of exerting neuroprotection in both the central and peripheral nervous…
Overview
AB Science is developing its lead compound masitinib in veterinary medicine. Since 2008 in Europe and since 2010 in the USA, masitinib is registered in a canine cancer called mast cell tumor, the most common cutaneous cancer in dogs. The drug is marketed by AB Science under the brand Masivet® in Europe and Kinavet in the…
Masitinib in Oncology
Prostate cancer is one of the most common types of cancer in men. Masitinib is currently investigated in first-line metastatic castrate-resistant prostate cancer (mCRPC). This patient population consists of patients who have disease progression despite androgen depletion therapy (castration) treatment. There is still a need for more effective first-line treatment of mCRPC since recent therapies…
Masitinib in Inflammatory Diseases
The severity of asthma can be graded from mild intermittent disease, with little impact on everyday life, through to severe disease with permanent symptoms and serious limitation of normal activities. Data suggests that mast cells are involved in allergic and anaphylactic reactions, playing an important role in hypersensitivity and inflammatory processes of the disease and…
AB8939
AB8939 is a new small-molecule drug that binds to tubulin and induces a rapid destabilisation of microtubules. Through disorganisation of microtubules, AB8939 is able to induce the apoptosis at nanomolar concentration of a wide panel of tumor cell lines, in particular hematopoietic tumor cell lines (i.e. cancers that affect the blood and lymph system) and…
Calendrier Financier
Choisir une année : 2017 2016 2015 2014 2013 Calendrier financier 2017 01/01/2017 – Calendrier financier pour l’année 2017 Calendrier financier 2016 23/02/2016 – Calendrier financier pour l’année 2016 Calendrier financier 2015 29/01/2015 – Calendrier financier pour l’année 2015 Calendrier financier 2014 29/11/2013 – Calendrier financier pour l’année 2014 Calendrier financier 2015 21/12/2012 – Calendrier…